Bristol Myers Squibb Co.

BMY · NYSE · ·

Compare

$62.34-0.9%Nov 12 close

Figures through September 30, 2026, from the 10-Q filed October 29, 2026

1W: +0.3%
1M: +5.2%

Bristol Myers Squibb Co. (BMY) stock — is it a good business? — InspectStocks

Bristol Myers Squibb Co.

BMY · NYSE · ·

Compare

$62.34-0.9%Nov 12 close

Figures through September 30, 2026, from the 10-Q filed October 29, 2026

1W: +0.3%
1M: +5.2%

Just reported

Q3 2026 results

From Bristol Myers Squibb's results release of October 29, 2026; its quarterly report has since been filed.

Revenue
Actual
$13.07B
+6.9% y/y
+0.7% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$1.05
-2.8% y/y
-35% q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$49B – $50BRaised +5.9%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

How it makes money

Prescription medicines, plus royalties and alliance-related revenue100%

Shares of revenue are estimates for FY2025, not figures from a filing.

Competes with

What it sells6

Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.

Show 3 more

Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.

Who buys it5

Wholesalers and distributors that buy medicines for onward sale to pharmacies, hospitals and other care providers.
Specialty pharmacies that dispense certain medicines, including products subject to restricted distribution programs.
Retail pharmacies, hospitals and clinics that purchase or dispense medicines.

Show 2 more

Government agencies and public health programs that buy medicines or cover their cost.
Patients in the United States, including cash-paying patients using direct-to-patient access for certain products.

What it stands on, and what could break it

What the business leans on

1Patent rights and regulatory approvals protect many branded medicines from competing copies; generic competition can reduce sales when that protection ends.
2Access to insurance coverage and placement on health-plan medicine lists affect whether patients can obtain products and what the company receives for them.
3U.S. sales rely on a small group of wholesalers: the three largest represented about 90% of U.S. product gross sales (six months ended June 30, 2026, high).
4The company relies on outside suppliers for ingredients or drug substances for products including Eliquis, Opdivo, Yervoy, Pomalyst, Sprycel, Camzyos and Cobenfy.
5Some medicines are developed or sold with partners, which can bring shared costs or royalties and affect the company's rights to sell a product.

What could go wrong

1Generic competition is already reducing sales of products including Revlimid, Pomalyst, Sprycel and Abraxane. Eliquis also faces generic competition in parts of Europe, and certain U.S. generic makers have settlement agreements allowing future launches.
2Government pricing rules, rebates and other limits can reduce the prices or reimbursement Bristol Myers Squibb receives. Medicare price-setting applies to Eliquis and Pomalyst, and Orencia has been selected for a future government price negotiation.
3Clinical trials can fail or be delayed, and regulators may not approve new medicines or expanded uses. That could make it harder for the company to replace sales of older medicines as they lose protection from generic competition.

Full financial statements →

About Bristol Myers Squibb Co.

Bristol Myers Squibb researches, develops, manufactures and sells prescription medicines around the world. Its medicines treat diseases including cancer, blood disorders, immune conditions, heart disease and schizophrenia. It sells mainly to wholesalers, distributors and pharmacies, and also earns royalties and other revenue through partnerships.

Head office: Lawrence Township, New Jersey (Princeton area)
Founded: 1887 (predecessor business; incorporated as Bristol-Myers Company in 1933)
Employees: Approximately 32,500 (December 31, 2025, high)
Listed on: NYSE
Financial year ends: December 31

Built from Bristol Myers Squibb Co.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Just reported

Q3 2026 results

From Bristol Myers Squibb's results release of October 29, 2026; its quarterly report has since been filed.

Revenue
Actual
$13.07B
+6.9% y/y
+0.7% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$1.05
-2.8% y/y
-35% q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$49B – $50BRaised +5.9%

Keep exploring

The themes Bristol Myers Squibb is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

How it makes money

Prescription medicines, plus royalties and alliance-related revenue100%

Shares of revenue are estimates for FY2025, not figures from a filing.

Competes with

What it sells6

Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.

Show 3 more

Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.

Who buys it5

Wholesalers and distributors that buy medicines for onward sale to pharmacies, hospitals and other care providers.
Specialty pharmacies that dispense certain medicines, including products subject to restricted distribution programs.
Retail pharmacies, hospitals and clinics that purchase or dispense medicines.

Show 2 more

Government agencies and public health programs that buy medicines or cover their cost.
Patients in the United States, including cash-paying patients using direct-to-patient access for certain products.

What it stands on, and what could break it

What the business leans on

1Patent rights and regulatory approvals protect many branded medicines from competing copies; generic competition can reduce sales when that protection ends.
2Access to insurance coverage and placement on health-plan medicine lists affect whether patients can obtain products and what the company receives for them.
3U.S. sales rely on a small group of wholesalers: the three largest represented about 90% of U.S. product gross sales (six months ended June 30, 2026, high).
4The company relies on outside suppliers for ingredients or drug substances for products including Eliquis, Opdivo, Yervoy, Pomalyst, Sprycel, Camzyos and Cobenfy.
5Some medicines are developed or sold with partners, which can bring shared costs or royalties and affect the company's rights to sell a product.

What could go wrong

1Generic competition is already reducing sales of products including Revlimid, Pomalyst, Sprycel and Abraxane. Eliquis also faces generic competition in parts of Europe, and certain U.S. generic makers have settlement agreements allowing future launches.
2Government pricing rules, rebates and other limits can reduce the prices or reimbursement Bristol Myers Squibb receives. Medicare price-setting applies to Eliquis and Pomalyst, and Orencia has been selected for a future government price negotiation.
3Clinical trials can fail or be delayed, and regulators may not approve new medicines or expanded uses. That could make it harder for the company to replace sales of older medicines as they lose protection from generic competition.

Full financial statements →

About Bristol Myers Squibb Co.

Head office: Lawrence Township, New Jersey (Princeton area)
Founded: 1887 (predecessor business; incorporated as Bristol-Myers Company in 1933)
Employees: Approximately 32,500 (December 31, 2025, high)
Listed on: NYSE
Financial year ends: December 31

Bristol Myers Squibb Co.

Bristol Myers Squibb Co.

Q3 2026 results

Revenue

EPS, GAAP

Company outlook

How it makes money

Competes with

What it sells6

Who buys it5

What it stands on, and what could break it

What the business leans on

What could go wrong

About Bristol Myers Squibb Co.

Q3 2026 results

Revenue

EPS, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells6

Who buys it5

What it stands on, and what could break it

What the business leans on

What could go wrong

About Bristol Myers Squibb Co.

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Growth & cash — 3 of 5

Business trend

Share price and grade over time